• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Front Microbiol . A synergistic therapy against influenza virus A/H1N1/PR8 by a HA1 specific neutralizing single-domain VL and an RNA hydrolyzing sc

tetano

Editor, Senior Moderator
Front Microbiol


. 2024 Apr 19:15:1355599.
doi: 10.3389/fmicb.2024.1355599. eCollection 2024. A synergistic therapy against influenza virus A/H1N1/PR8 by a HA1 specific neutralizing single-domain V[SUB]L[/SUB] and an RNA hydrolyzing scFv

Phuong Thi Hoang[SUP] 1 2 [/SUP], Quynh Xuan Thi Luong[SUP] 1 [/SUP], Ramadhani Qurrota Ayun[SUP] 1 [/SUP], Yongjun Lee[SUP] 1 [/SUP], Kwang-Ji Oh[SUP] 1 2 [/SUP], Taehyun Kim[SUP] 2 [/SUP], Taek-Kyun Lee[SUP] 3 [/SUP], Sukchan Lee[SUP] 1 [/SUP]



Affiliations
Abstract

The emergence of anti-influenza drug-resistant strains poses a challenge for influenza therapy due to mutations in the virus's surface protein. Recently, there has been increasing interest in combination therapy consisting of two or more drugs as a potential alternative approach, aiming to enhance therapeutic efficacy. In this study, we investigated a novel synergistic therapy with a vertical effect using a single-domain VL-HA1-specific antibody against H1N1/PR8 and a horizontal effect using an RNA catalytic antibody with broad-spectrum influenza antiviral drug. We isolated a single-domain VL-HA1-specific (NVLH8) antibody binding to the virus particles showing a neutralizing activity against influenza virus A, specifically H1N1/PR8, as determined by the reduction in plaque number and lower viral HA protein expression in vitro. The neutralizing antibody likely prevented the viral entry, specifically at the viral genome-releasing step. Additionally, the 3D8 scFv hydrolyzed viral RNAs in the cytoplasm, including mRNA, vRNA, and cRNA in MDCK cells. The combined treatment of neutralizing antibodies for a vertical effect and 3D8 scFv for a horizontal effect produced a synergistic effect providing a novel approach against viral diseases when compared with a single treatment. Our results indicated that combining treatment, in particular two proteins exhibiting different mechanisms of action increased the antiviral activity against the influenza virus.

Keywords: 3D8 scFv; bio-panning; influenza virus; neutralizing antibodies; synergistic effect.

 
Back
Top